New therapeutic key for cystic fibrosis: a role for lipoxins

One of the hallmarks of cystic fibrosis is the propensity of patients to develop lung infections with Pseudomonas aeruginosa, which eventually compromises lung function. New data suggest loss of CFTR impairs lipoxin production, thus preventing resolution of lung inflammation and creating an environment susceptible to further infection.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: The pathophysiology of CF-affected airway systems and bacterial infection.

References

  1. 1

    Riordan, J.R. et al. Science 245, 1066–1073 (1989).

  2. 2

    Gibson, R.L., Burns, J.L. & Ramsey, B.W. Am. J. Respir. Crit. Care Med. 168, 918–951 (2003).

  3. 3

    Verkman, A.S., Song, Y. & Thiagarajah, J.R. Am. J. Physiol. Cell Physiol. 284, C2–15 (2003).

  4. 4

    Karp, C.L. Nat. Immunol. 5, 388–392 (2004).

  5. 5

    Serhan, C.N. Prostaglandins Other Lipid Mediat. 68–69, 433–455 (2002).

  6. 6

    Nagase, T. et al. Biochem. Biophys. Res. Commun. 168, 485–489 (1990).

  7. 7

    Serhan, C.N. et al. J. Exp. Med. 196, 1025–1037 (2002).

  8. 8

    Samuelsson, B., Dahlen, S.E., Lindgren, J.A., Rouzer, C.A. & Serhan, C.N. Science 237, 1171–1176 (1987).

  9. 9

    Shimizu, T. & Wolfe, L.S. J. Neurochem. 55, 1–15 (1990).

  10. 10

    Nagase, T. et al. Nat. Immunol. 1, 42–46 (2000).

  11. 11

    Nagase, T. et al. Nat. Med. 8, 480–484 (2002).

  12. 12

    Konstan, M.W., Byard, P.J., Hoppel, C.L. & Davis, P.B. N. Engl. J. Med. 332, 848–854 (1995).

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Takai, D., Nagase, T. & Shimizu, T. New therapeutic key for cystic fibrosis: a role for lipoxins. Nat Immunol 5, 357–358 (2004). https://doi.org/10.1038/ni0404-357

Download citation

Further reading